CN104684552B - 组合及其用途 - Google Patents

组合及其用途 Download PDF

Info

Publication number
CN104684552B
CN104684552B CN201380050577.7A CN201380050577A CN104684552B CN 104684552 B CN104684552 B CN 104684552B CN 201380050577 A CN201380050577 A CN 201380050577A CN 104684552 B CN104684552 B CN 104684552B
Authority
CN
China
Prior art keywords
seq
sequence
antibody
melphalan
specific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380050577.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104684552A (zh
Inventor
简·恩德尔
利莎·罗杰克加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Publication of CN104684552A publication Critical patent/CN104684552A/zh
Application granted granted Critical
Publication of CN104684552B publication Critical patent/CN104684552B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380050577.7A 2012-09-25 2013-09-24 组合及其用途 Active CN104684552B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705172P 2012-09-25 2012-09-25
US61/705,172 2012-09-25
US201361774595P 2013-03-08 2013-03-08
US61/774,595 2013-03-08
PCT/EP2013/069858 WO2014048921A1 (en) 2012-09-25 2013-09-24 Combinations and uses thereof

Publications (2)

Publication Number Publication Date
CN104684552A CN104684552A (zh) 2015-06-03
CN104684552B true CN104684552B (zh) 2018-08-07

Family

ID=49237209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380050577.7A Active CN104684552B (zh) 2012-09-25 2013-09-24 组合及其用途

Country Status (22)

Country Link
US (1) US9579378B2 (https=)
EP (1) EP2900232B1 (https=)
JP (1) JP6426093B2 (https=)
KR (1) KR102171669B1 (https=)
CN (1) CN104684552B (https=)
AU (1) AU2013322806C1 (https=)
BR (1) BR112015006731A2 (https=)
CA (1) CA2885792C (https=)
DK (1) DK2900232T3 (https=)
ES (1) ES2658953T3 (https=)
HR (1) HRP20171964T1 (https=)
HU (1) HUE036518T2 (https=)
IL (1) IL237926B (https=)
LT (1) LT2900232T (https=)
MX (1) MX368288B (https=)
NZ (1) NZ706147A (https=)
PL (1) PL2900232T3 (https=)
PT (1) PT2900232T (https=)
RU (1) RU2650618C2 (https=)
SG (1) SG11201502163QA (https=)
WO (1) WO2014048921A1 (https=)
ZA (1) ZA201501980B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017149122A1 (en) * 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CN113194925B (zh) * 2018-12-14 2025-03-07 莫佛塞斯公司 抗体制剂
EP3938394A1 (en) * 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2010061360A1 (en) * 2008-11-28 2010-06-03 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
WO2010061357A1 (en) * 2008-11-28 2010-06-03 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
WO2011154453A1 (en) * 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
EP3569245A1 (en) 2006-09-26 2019-11-20 Genmab A/S Combination treatment of cd38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042309A2 (en) * 2005-10-12 2007-04-19 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2010061360A1 (en) * 2008-11-28 2010-06-03 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
WO2010061357A1 (en) * 2008-11-28 2010-06-03 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
WO2011154453A1 (en) * 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2012041800A1 (en) * 2010-09-27 2012-04-05 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Also Published As

Publication number Publication date
ES2658953T3 (es) 2018-03-13
EP2900232A1 (en) 2015-08-05
IL237926B (en) 2020-04-30
SG11201502163QA (en) 2015-04-29
NZ706147A (en) 2018-10-26
AU2013322806C1 (en) 2018-03-08
HUE036518T2 (hu) 2018-07-30
US20150238603A1 (en) 2015-08-27
AU2013322806B2 (en) 2017-11-30
CN104684552A (zh) 2015-06-03
DK2900232T3 (en) 2018-02-05
LT2900232T (lt) 2018-02-26
KR102171669B1 (ko) 2020-10-30
PL2900232T3 (pl) 2018-05-30
JP2015530399A (ja) 2015-10-15
CA2885792C (en) 2021-09-28
RU2015110981A (ru) 2016-11-20
ZA201501980B (en) 2017-11-29
CA2885792A1 (en) 2014-04-03
RU2650618C2 (ru) 2018-04-16
PT2900232T (pt) 2018-02-09
JP6426093B2 (ja) 2018-11-28
HRP20171964T1 (hr) 2018-02-23
MX2015003589A (es) 2015-08-12
HK1210949A1 (en) 2016-05-13
EP2900232B1 (en) 2017-11-15
US9579378B2 (en) 2017-02-28
AU2013322806A1 (en) 2015-04-09
KR20150090030A (ko) 2015-08-05
BR112015006731A2 (pt) 2017-07-04
WO2014048921A1 (en) 2014-04-03
MX368288B (es) 2019-09-27
IL237926A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
CN104684552B (zh) 组合及其用途
US11591406B2 (en) Treatment for multiple myeloma (MM)
WO2025002280A1 (en) Combination therapies for the treatment of cancer
AU2024311205A1 (en) Treatment method and use of pharmaceutical combination containing conjugate
CN113993543B (zh) 使用抗cd38抗体的组合疗法
WO2024041652A1 (en) Methods of cancer treatment
HK1210949B (zh) 组合及其用途
AU2023278019A1 (en) Combination therapies for the treatment of non-small cell lung cancer
AU2024307849A1 (en) Therapeutic combination, and use and treatment method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210949

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: Praneger, Germany

Patentee after: Morphosys AG

Address before: Martins Reed Germany

Patentee before: Morphosys AG

CP02 Change in the address of a patent holder